- Home
- About BBRB
- Programs
- Biospecimen Research Network
- Overview
- Biospecimen Science
- BRN Research Projects
- Overview
- Impact of Human Blood Specimen Collection, Processing
and Storage on Protein Integrity and Implications for Use
in Clinical Research — Dr. Daniel Chelsky - Credentialing Plasma and Serum Biospecimen Banks for
Proteomics Analysis — Dr. Katherine Williams - Effects of Pre-analytic Variables on Circulating
microRNAs — Christine Abrosone and Hua Zhao - Human Biospecimen Integrity in Breast Cancer Tissues
Analytical Variance on Microarray-Based Pharmacogenomics
Tests of Breast Cancer — Dr. Fraser Symmans - Intrinsic and Extrinsic controls for Formalin Fixed,
Paraffin Embedded (FFPE) Tissue — Dr. David Rimm - Research Studies on the Effects of Intraoperative Ischemia
time on Gene and Protein Expression Patterns in Liver and
Colon Tissue — Dr. Hartmut Juhl
- Biospecimen Research Database
- Lifecycle of Biospecimens
- BRN Symposia
- BPV
- caHUB
- NCI Best Practices
- Biospecimen Research Network
- Best Practices
- Table of Contents
- Introduction
- Scope, Applicability, Implementation
- Technical and Operational Best Practices
- Ethical, Legal, and Policy Best Practices
- Web Resources
- Glossary of Terms
- Acronym List
- Appendix 1: Minimal Clinical Data Set (PDF)
- Appendix 2. Additional Resources Related to Ethical, Legal, and Policy
- Appendix 3: Governance Plan (PDF)
- Appendix 4: Sample Material Transfer Agreement (PDF)
- Appendix 5: Example of Biospecimen Evidence-Based Practice (PDF)
- Appendix 6: CAP Biorepository Accreditation Program Checklist (PDF)
- References
- 2016 Best Practices (PDF)
- Best Practices Archive
- Best Practices Translations
- News and Events
- Public Resources
- Patient Corner
- Biospecimen and Biorepository Basics
- Donating Biospecimens
- Ethical, Legal, and Social Implications Related to Biorepositories and Biospecimens
- Reducing Health Disparities
- Biospecimens in Cancer Research and Precision Medicine
- Additional Resources and Links for Patients
- Frequently Asked Questions (FAQs)
- Patient Corner Glossary
Last Updated: 01/25/16
cancer Biomedical Informatics Grid™ (caBIG™)
One of the most challenging issues for researchers and biorepositories has been the absence of information technology tools and infrastructure to facilitate the appropriate collection, processing, archiving, and dissemination of biospecimens to the research community, not only within an individual medical institution but also in a network across multiple institutions.
- caTissue core will address all aspects of donor enrollment and informed consent, collection and tracking of samples.
- caTissue CAE will address annotation of biospecimens with molecular and clinical data.
- caTIES will allow extraction of structured data from free text pathology reports.
caBIG™ tools are designed with security considerations to support patient privacy and data access restrictions, including those aspects covered by the Common Rule and HIPAA (Health Insurance Portability and Accountability Act). Visit http://www.hipaa.org/ to learn more.
For additional information about caBIG™, please also visit the caBIG™ Toolbox.
Related Initiatives
- The Cancer Genome Atlas [TCGA]
- Clinical Proteomic Technologies for Cancer [CPTC]
- NCI Community Cancer Centers Program (NCCCP)
- Innovative Molecular Analysis Technologies Program (IMAT)
- Alliance for Nanotechnology in Cancer
- Translational Research Working Group (TRWG)
- caBIG™
- FDA/NCI Interagency Oncology Task Force (IOTF)